• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
  • Aramchol™ reduces fibrosis progression in 24 weeks EuropeanPharmaceuticalReview
    November 02, 2021
    Galmed Pharmaceuticals has announced results from the first 16 patients in the open-label part of the ARMOR​ Phase III study who underwent a scheduled post-baseline biopsy and were treated with Aramchol™ for fibrosis.
  • Galmed Initiated Study of Aramchol in Subjects with NASH and Fibrosis americanpharmaceuticalreview
    September 27, 2019
    Galmed Pharmaceuticals announced the initiation of its Phase 3/4 ARMOR clinical study to evaluate the efficacy and safety of Aramchol in subjects with NASH and fibrosis. This double-blind, placebo-controlled ...

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service